Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 05 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-mar-05-2025-1

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 05, 2025, titled "Zydus receives final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg".

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases